• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

PLoS Pathog . A SARS-CoV-2 variant-induced NTD-targeting antibody enhances viral infection via a distinctive binding mode

tetano

Editor, Senior Moderator
PLoS Pathog


. 2026 Feb 10;22(2):e1013828.
doi: 10.1371/journal.ppat.1013828. eCollection 2026 Feb.
A SARS-CoV-2 variant-induced NTD-targeting antibody enhances viral infection via a distinctive binding mode

Wenting Li[SUP] 1 [/SUP], Congcong Liu[SUP] 1 [/SUP], Yaning Li[SUP] 2 3 [/SUP], Qi Gui[SUP] 1 4 [/SUP], Lin Cheng[SUP] 1 [/SUP], Qing Fan[SUP] 1 [/SUP], Bing Zhou[SUP] 1 [/SUP], Haiyan Wang[SUP] 1 [/SUP], Xiangyang Ge[SUP] 1 [/SUP], Zheng Zhang[SUP] 1 5 6 [/SUP], Renhong Yan[SUP] 2 [/SUP], Bin Ju[SUP] 1 5 [/SUP]


Affiliations
Abstract

SARS-CoV-2 infection elicits both neutralizing and non-neutralizing monoclonal antibodies (mAbs), primarily targeting to the N-terminal domain (NTD), receptor-binding domain (RBD), and S2 subunit of the spike protein. Notably, a unique subset of NTD-targeting mAbs isolated from prototype Wuhan-Hu-1 strain infected donors displayed a capacity of facilitating the viral infection independent of the fragment crystallizable (Fc) region in vitro. However, the rapid evolution of SARS-CoV-2 variants, particularly with NTD mutations, has led to widespread immune evasion. Whether SARS-CoV-2 variants could still induce NTD-targeting infection-enhancing antibodies (NIEAs) remains unclear. Here, we identified a distinctive NIEA, ConD-854, from a Delta variant primarily infected donor, with broad infection-enhancing activities against most pre-Omicron variants but not against post-Omicron variants. Structural and functional analysis revealed that ConD-854 enhanced the viral infection through an Fc-independent bivalent binding mechanism with a largely shared recognition epitope, but its heavy-light chain orientation was nearly perpendicular relative to the reported prototype strain-induced NIEAs. Collectively, our findings demonstrated that the primary infection of Delta variant could still induce the NIEAs targeting the similar epitope as those elicited by prototype strain infection. Mutations in Delta NTD were located outside the infection-enhancing epitope and did not affect the induction of NIEAs. Remarkably, we defined a distinctive structural paradigm for an NIEA to recognize the viral epitope. These results enriched our understanding of antiviral antibodies and provided insights for future vaccine design.


 
Back
Top